开放获取期刊获得更多读者和引用
700 种期刊 和 15,000,000 名读者 每份期刊 获得 25,000 多名读者
Christen L. Ebens, Julia A. Riedl, Jakub Tolar
Mesenchymal Stromal Cell(MSC) therapies to modulate inflammation and promote tissue regeneration in Recessive Dystrophic Epidermolysis Bullosa(RDEB) are under active investigation in clinical trials. However, optimal tissue source and fundamental mechanisms of clinical benefit of MSCs require additional investigation. Riedl et al.recently published “ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and localimmunomodulation for Recessive Dystrophic Epidermolysis Bullosa treatment,” in Stem Cells [1] highlightingdifferences in homing of MSCs, impact on local macrophages, and distinct transcriptional profiles related to tissue oforigin (skin dermis versus bone marrow). Elucidation of these critical features and underlying mechanisms will aid intranslation of MSC cellular therapies to promote wound healing in RDEB.